Elite Pharmaceuticals, Inc. (ELTP)
0.3247
0.00 (0.00%)
USD |
OTCM |
Nov 20, 16:00
Elite Pharmaceuticals Enterprise Value : 320.08M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 320.08M |
| November 19, 2026 | 319.20M |
| November 18, 2026 | 356.47M |
| November 17, 2026 | 368.48M |
| November 16, 2026 | 364.55M |
| November 13, 2026 | 320.28M |
| November 12, 2026 | 234.21M |
| November 11, 2026 | 228.83M |
| November 10, 2026 | 228.83M |
| November 09, 2026 | 225.40M |
| November 06, 2026 | 226.35M |
| November 05, 2026 | 224.61M |
| November 04, 2026 | 231.81M |
| November 03, 2026 | 231.95M |
| November 02, 2026 | 207.39M |
| October 30, 2026 | 217.95M |
| October 29, 2026 | 215.90M |
| October 28, 2026 | 234.11M |
| October 27, 2026 | 231.59M |
| October 26, 2026 | 238.74M |
| October 23, 2026 | 239.38M |
| October 22, 2026 | 236.91M |
| October 21, 2026 | 234.21M |
| October 20, 2026 | 234.48M |
| October 19, 2026 | 240.42M |
| Date | Value |
|---|---|
| October 16, 2026 | 244.18M |
| October 15, 2026 | 243.94M |
| October 14, 2026 | 238.74M |
| October 13, 2026 | 244.99M |
| October 12, 2026 | 244.99M |
| October 09, 2026 | 245.09M |
| October 08, 2026 | 255.76M |
| October 07, 2026 | 244.20M |
| October 06, 2026 | 234.21M |
| October 05, 2026 | 211.65M |
| October 02, 2026 | 216.60M |
| October 01, 2026 | 214.83M |
| September 30, 2026 | 230.77M |
| September 29, 2026 | 224.07M |
| September 28, 2026 | 237.42M |
| September 25, 2026 | 244.66M |
| September 24, 2026 | 232.45M |
| September 23, 2026 | 234.73M |
| September 22, 2026 | 232.63M |
| September 21, 2026 | 227.51M |
| September 18, 2026 | 233.22M |
| September 17, 2026 | 235.81M |
| September 16, 2026 | 230.53M |
| September 15, 2026 | 234.52M |
| September 14, 2026 | 246.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.741B |
| Corcept Therapeutics, Inc. | 6.596B |
| Veru, Inc. | 9.969M |
| Johnson & Johnson | 678.48B |
| Eli Lilly & Co. | 1.313T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.32M |
| Revenue (Quarterly) | 40.08M |
| Total Expenses (Quarterly) | 22.76M |
| EPS Diluted (Quarterly) | 0.0068 |
| Gross Profit Margin (Quarterly) | 38.93% |
| Profit Margin (Quarterly) | 43.21% |
| Earnings Yield | 8.53% |
| Operating Earnings Yield | 10.33% |
| Normalized Earnings Yield | 2.494 |